GlaxoSmithKline nabs 'breakthrough' label for Tafinlar in lung cancer

GlaxoSmithKline's ($GSK) new cancer drug Tafinlar won the FDA's "breakthrough therapy" designation for use in lung cancer patients. Already approved to treat melanoma, the drug snapped up a new approval last week for use in combination with another GSK melanoma treatment, Mekinist. Report